Monthly Archives - August 2020

Veteran Health Administration Expanding Homecare Pain Management Program with Sustained Acoustic Medicine (SAM) Ultrasound Patch Technology During COVID-19

Military veteran Dr. Ervin Rodriguez, who served as a First Sergeant in the United States Army, experienced a life-changing improvement in the state of multiple chronic soft-tissue injury sites after treating them with the Sustained Acoustic Medicine (SAM®) wearable, multi-hour, ultrasound device manufactured by ZetrOZ Systems in Trumbull, CT, USA. Read more >>
Read more...

Cannabis and Science

In the 1980s and 1990s, researchers identified cannabinoid receptors in humans (CB1 for THC and CB2 for CBD). What they were uncovering was the human body’s own endocannabinoid system (ECS). “It’s a system as ancient as our immune system and our central nervous system. They co-evolved and our endocannabinoid system acts as a bridge between the two,” says Yuval Cohen, CEO and Director of Corbus Pharmaceuticals. Read more >>
Read more...

Kalion Inc. Receives NSF Phase II SBIR Grant to Develop Bio-based Glucaric Acid

Kalion Inc. has been awarded a National Science Foundation (NSF) Phase II Small Business Research (SBIR) grant for $746,822 to conduct research and development work improving the bio-based production of glucaric acid. Glucaric acid and its related compounds enhance sustainability as well as improve the chemical properties of products ranging from water treatment, polymers & textiles, coatings, detergents and pharmaceuticals. Read more >>
Read more...

eSight 4 Earns CE Mark Approval to Bring New Wearable Device to Europe

eSight, a cutting-edge vision enhancement platform, today announces it has received CE Mark approval for eSight 4, the company's latest assistive technology device that's clinically proven to significantly enhance vision for those living with low vision and legal blindness. The CE Mark certification signifies that eSight 4 has been assessed to meet high safety, health and environmental protection requirements in Europe and is considered an essential requirement for companies to sell and distribute medical products within the European Economic Area...
Read more...

Corbus Pharmaceuticals Completes Enrollment in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced the completion of subject enrollment in DETERMINE, a Phase 3 study assessing the efficacy and safety of lenabasum for the treatment of dermatomyositis. Read more >>
Read more...